Isonicotinic Acid Derivatives as Antimicrobial and Antitubercular Agents: Synthetic Strategies, Structure–Activity Relationships and Drug-Discovery Perspectives
DOI:
https://doi.org/10.62752/ijphi.v3i2.274Keywords:
Isonicotinic acid derivatives; Antimicrobial activity; Antitubercular agents; Structure–activity relationship; 1,3,4-Oxadiazole.Abstract
Due to the increasing demand for effective antitubercular agents, and the emergence of drug resistance, structurally diverse heterocyclic compounds have been explored. Isonicotinic acid derivatives are an important subclass of medicinal chemistry scaffolds as they are known to be associated with the drug isoniazid and the possibility of making structural modifications on these scaffolds. This review is an overview of the synthetic approaches, antimicrobial activity and structure–activity relationship of selected derivatives of Isonicotinic acid especially hydrazides and heterocyclic derivatives, particularly that of 1,3,4-oxadiazole derivatives. Results obtained from published studies of the influence of functional group modifications on biological activity and physicochemical properties of the compound are discussed. A special emphasis is laid on reported antibacterial activities, antifungal activities and antitubercular activities, separating general antimicrobial activities from those specifically shown against Mycobacterium tuberculosis. In addition, the utilization of molecular docking and in silico Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) predictions in initial screening of potential compound is explored. Experimental validation, selectivity, drug-like properties and the transfer of computational results to biological efficacy are taken into consideration. This review, by combining synthetic chemistry with the existing pharmacological evidence, aims to pinpoint promising structural elements, expose the existing lacunae and offer a targeted overview for the rational design and development of Isonicotinic acid derivatives as potential antimicrobial and antitubercular agents.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 © IJPHI GLOBAL PUBLISHER PVT. LTD.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in the International Journal of Pharmaceutical and Healthcare Innovation (IJPHI) are licensed under the Creative Commons Attribution–NonCommercial 4.0 International License (CC BY-NC 4.0). Authors retain copyright of their work and grant the journal the right of first publication. The published material may be used, shared, and reproduced for non-commercial purposes with proper attribution.
© IJPHI GLOBAL PUBLISHER PVT. LTD.








